Evidence map›Paper›PMID 33098283›Full record

ArticleTurkish journal of medical sciences2021

Role of mir-33a, mir-203b, mir361-3p, and mir-424 in hepatocellular carcinoma

Burhanettin Yalçınkaya, Esra Güzel, Didem Taştekin, Sadrettin Pençe

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Burhanettin YalçınkayaScientific and Technological Research Council of Turkey (TÜBİTAK) National Metrology Institute (UME), Kocaeli, TurkeyORCID 0000-0002-3744-6634
Esra GüzelInstitute of Health Sciences, University of Health Sciences, İstanbul, TurkeyORCID 0000-0002-0909-8935
Didem TaştekinInstitute of Oncology, İstanbul University, İstanbul, TurkeyORCID 0000-0002-9522-9849
Sadrettin PençeAziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, TurkeyORCID 0000-0001-9453-4166
Istanbul Medeniyet University · TRIstanbul University · TRSağlık Bilimleri Üniversitesi · TRTübitak National Metrology Institute · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Hepatocellular carcinoma (HCC) is one of the most aggressive cancer types. MicroRNAs (miRNAs) are small noncoding regulatory RNAs that function posttranscriptionally. miRNA deregulation was observed in the development and progression of HCC. In this study, we aimed to investigate the expression levels of four miRNAs (mir-33a, mir-203b, mir361-3p, and mir-424) in HCC patients in comparison to healthy individuals. Materials and methods: Venous blood samples were collected from both HCC patients and healthy individuals. In order to determine the relative expression levels of mir-33a, mir-203b, mir361-3p, and hsa-mir-424 in HCC patients, probe-based quantitative real time PCR (qRT-PCR) was performed. The cycle threshold (Ct) results were analyzed according to the 2−∆∆Ct method and statistical analyses were performed by SPSS Statistics version 15 for Windows. Results: qRT-PCR analysis revealed that the expression levels of mir-33a (fold change: 7.3 and P < 0.001), mir-203b (fold change: 4.6 and P < 0.001), and mir361-3p (fold change: 5.1 and P < 0.001)were downregulated compared to healthy individuals and mir-424 did not show any significant change between HCC patients and controls. Conclusion: Our results indicated that mir-33a, mir-203b, and mir-361-3p may significantly contribute to tumor pathogenesis in HCC and have potential to be used as a noninvasive biomarker for cancer therapy.

Indexed as

AdultAgedCarcinoma, HepatocellularCase-Control StudiesCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionMicroRNAsMIRN33a microRNA, humanMIRN361 microRNA, humanMIRN424 microrna, humanHCCmir-203bMir-33amir361-3pmir-424qRT-PCR

Identifiers

PMID33098283
PMCPMC8203149
OpenAlexW3094531751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.